AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on AbbVie, with 23 buy ratings, two strong-buy ratings and six hold ratings among 31 brokerages. The average one-year price target is $272.66.
• AbbVie exceeded quarterly expectations, reporting adjusted EPS of $3.65 and revenue of $16.99 billion, up 10.2% year over year. The company also declared a quarterly dividend of $1.73 per share, representing a 2.6% annualized yield.
• FDA approval of JUVMO for Parkinson’s disease creates a potential new growth driver, though analysts expect a gradual revenue ramp. The company is also expanding its longer-term pipeline through an AI drug-discovery collaboration with Iambic.

AbbVie Inc. (NYSE:ABBV - Get Free Report) has been assigned an average rating of "Moderate Buy" from the thirty-one brokerages that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $272.66.

A number of brokerages have recently issued reports on ABBV. Wolfe Research raised AbbVie from a "peer perform" rating to an "outperform" rating and boosted their price objective for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Citigroup raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Wells Fargo & Company boosted their price target on AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Argus increased their price target on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Finally, Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th.

AbbVie Stock Up 0.8%

ABBV opened at $266.39 on Tuesday. AbbVie has a twelve month low of $190.75 and a twelve month high of $269.39. The company has a fifty day moving average of $257.41 and a 200-day moving average of $233.59. The stock has a market cap of $470.65 billion, a PE ratio of 75.25, a price-to-earnings-growth ratio of 1.19 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts anticipate that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie's dividend payout ratio is currently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approval provides a new commercial growth opportunity. The FDA approved JUVMO (tavapadon), AbbVie’s once-daily Parkinson’s disease treatment and the first selective D1/D5 receptor agonist approved for adults with the condition. The drug is expected to launch in the U.S. in October and could eventually become a billion-dollar product, according to analyst commentary. Approval was supported by Phase 3 data showing improved daily functioning and more “on” time without troublesome dyskinesia. U.S. FDA Approves AbbVie's JUVMO for Parkinson's Disease
• Positive Sentiment: The Cerevel acquisition is beginning to deliver a key pipeline asset. JUVMO originated from AbbVie’s approximately $8.7 billion acquisition of Cerevel Therapeutics, giving investors evidence that the deal can add products in neuroscience and diversify revenue. AbbVie’s Cerevel Buyout Delivers FDA Approval
• Positive Sentiment: AbbVie is expanding its long-term research pipeline through AI. A multiyear collaboration with Iambic will use its Enchant AI platform to accelerate small-molecule drug discovery in immunology, neuroscience and oncology. The effort could improve pipeline productivity, although financial benefits are likely several years away. AI Could Give AbbVie a New Route to Long-Term Pipeline Growth
• Neutral Sentiment: AbbVie’s connection to ADARx offers potential pipeline visibility but limited immediate impact. AbbVie’s backing is highlighted as ADARx pursues a U.S. IPO targeting a valuation of up to $1.74 billion. The development may underscore AbbVie’s interest in external innovation, but it does not immediately change AbbVie’s earnings outlook. ADARx IPO and AbbVie’s Backing
• Negative Sentiment: JUVMO’s revenue ramp may be gradual. Analysts and management expect a potentially slow initial launch as physicians and patients adopt the new therapy, limiting near-term earnings contribution despite its long-term sales potential.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently made changes to their positions in the stock. Burk Holdings LLC acquired a new stake in AbbVie in the second quarter valued at approximately $30,000. Abound Financial LLC acquired a new position in shares of AbbVie during the fourth quarter worth approximately $32,000. Merkkuri Wealth Advisors LLC acquired a new position in shares of AbbVie during the first quarter worth approximately $34,000. Marquette Asset Management LLC lifted its holdings in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock worth $35,000 after purchasing an additional 48 shares in the last quarter. Finally, Phillip James Consulting Co. bought a new position in shares of AbbVie in the 4th quarter worth $36,000. Institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.